Adeno-associated virus vectors: Activity and applications in the CNS

Journal of Neuroscience Methods

Volumn 98, Issue 2, 2000, Pages 95-104

  Peel, Alyson L ^a   Klein, Ronald L ^b  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Adeno associated virus (AAV); Disease modeling; Gene therapy; Gene transfer; Neurodegenerative disease; Neurotrophic factor

Indexed keywords

NEUROTROPHIC FACTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; DEGENERATIVE DISEASE; GENE THERAPY; GENE TRANSFER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SPINAL CORD; TRANSGENE; TRANSGENIC ANIMAL;

EID: 0034212887     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0270(00)00183-7     Document Type: Article

References (66)

1. Allen JM, Debelak DJ, Reynolds TC, Miller AD. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by non-homologous recombination during AAV vector production. J Virol. 71:(9):1997;6816-6822.
2. Andersen JK, Frim DM, Isacson O, Breakefield XO. Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. Cell Mol Neurobiol. 13:(5):1993;503-515.
3. Atchison RW. The role of herpesviruses in adenovirus-associated virus replication in vitro. Virology. 42:(1):1970;155-156.
4. Bartlett JS, Samulski RJ, McCown TJ. Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther. 9:(8):1998;1181-1186.
5. Bilang-Bleuel A, Revah F, Colin P, Locquet I, Robert JJ, Mallet J, et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA. 94:(16):1997;8818-8823.
6. Blömer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol. 71:(9):1997;6641-6649.
7. Brenner M, Kisseberth WC, Su Y, Besnard F, Messing A. GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci. 14:1994;1030-1037. (3 Pt 1).
8. Carey RJ. Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance. Brain Res. 568:(1-2):1991;205-214.
9. Casto BC, Atchison RW, Hammon WM. Studies on the relationship between adeno-associated virus type I (AAV-1) and adenoviruses. I. Replication of AAV-1 in certain cell cultures and its effect on helper adenovirus. Virology. 32:(1):1967;52-59.
10. Chamberlin NL, Du B, de Lacalle S, Saper CB. Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS. Brain Res. 793:(1-2):1998;169-175.
11. Chen H, McCarty DM, Bruce AT, Suzuki K, Suzuki K. Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by adeno-associated virus. Gene Ther. 5:(1):1998;50-58.
12. Chen H, McCarty DM, Bruce AT, Suzuki K, Suzuki K. Oligodendrocyte-specific gene expression in mouse brain: use of a myelin-forming cell type-specific promoter in an adeno-associated virus. J Neurosci Res. 55:(4):1999;504-513.
13. Choi-Lundberg DL, Lin Q, Chang YN, Chiang YL, Hay CM, Mohajeri H, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science. 275:(5301):1997;838-841.
14. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther. 6:(10):1995;1329-1341.
15. Conway JE, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J Virol. 71:(11):1997;8780-8789.
16. Dhillon H, Minter RM, Topping D, Prima V, Moldawer LL, Muzyczka N, et al. Long-term correction of obesity using centrally delivered rAAV encoding anorexigenic cytokines. Am Soc Gene Ther Abstr. 2:1999;45a.
17. During MJ, Samulski RJ, Elsworth JD, Kaplitt MG, Leone P, Xiao X, et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther. 5:(6):1998;820-827.
18. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 70:(5):1996;3227-3234.
19. Flotte TR, Solow R, Owens RA, Afione S, Zeitlin PL, Carter BJ. Gene expression from adeno-associated virus vectors in airway epithelial cells. Am J Respir Cell Mol Biol. 7:(3):1992;349-356.
20. Ford T, Graham J, Rickwood D. Iodixanol: a non-ionic iso-osmotic centrifugation medium for the formation of self-generated gradients. Anal Biochem. 220:(2):1994;360-366.
21. Forss-Petter S, Danielson PE, Catsicas S, Battenberg E, Price J, Nerenberg M, et al. Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control. Neuron. 5:(2):1990;187-197.
22. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:(6514):1995;523-527.
23. Grimm D, Kern A, Rittner K, Kleinschmidt JA. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther. 9:(18):1998;2745-2760.
24. Guy J, Qi X, Hauswirth WW. Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis. Proc Natl Acad Sci USA. 95:(23):1998;13847-13852.
25. Haberman RP, McCown TJ, Samulski RJ. The adeno-associated virus terminal repeat contains promoter activity in vitro and in vivo. Soc Neurosci Abstr. 25:1999;2001.
26. Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA. 81:(20):1984;6466-6470.
27. Ikenaka K, Kagawa T. Transgenic systems in studying myelin gene expression. Dev Neurosci. 17:(3):1995;127-136.
28. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet. 8:(2):1994;148-154.
29. Klein RL, Meyer EM, Peel AL, Zolotukhin S, Meyers C, Muzyczka N, et al. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol. 150:(2):1998;183-194.
30. Klein RL, Muir D, King MA, Peel AL, Zolotukhin S, Möller JC, et al. Long-term actions of vector-derived NGF or BDNF on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain. Neuroscience. 90:1999a;815-821.
31. Klein RL, McNamara RK, King MA, Lenox RH, Muzyczka N, Meyer EM. Generation of aberrant sprouting in the adult rat brain by GAP-43 somatic gene transfer. Brain Res. 832:1999b;136-144.
32. Klein RL, Lewis MH, Muzyczka N, Meyer EM. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res. 847:(2):1999c;314-320.
33. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA. 87:(6):1990;2211-2215.
34. Lewin AS, Drenser KA, Hauswirth WW, Nishikawa S, Yasumura D, Flannery JG, LaVail MM. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat Med. 4:(8):1998;967-971.
35. Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA. 94:(25):1997;14083-14088.
36. Mandel RJ, Rendahl KG, Spratt SK, Snyder RO, Cohen LK, Leff SE. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci. 18:(11):1998;4271-4284.
37. Mandel RJ, Snyder RO, Leff SE. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp Neurol. 160:1999a;205-214.
38. Mandel RJ, Rendahl KG, Snyder RO, Leff SE. Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors. Exp Neurol. 159:1999b;47-64.
39. McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713:(1-2):1996;99-107.
40. McLaughlin SK, Collis P, Hermonat PL, Muzyczka N. Adeno-associated virus general transduction vectors: analysis of proviral structures. J Virol. 62:(6):1988;1963-1973.
41. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol. 158:1992;97-129.
42. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 108:1991;193-199.
43. Peel AL, Zolotukhin S, Schrimsher GW, Muzyczka N, Reier PJ. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 4:(1):1997;16-24.
44. Pereira DJ, McCarty DM, Muzyczka N. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J Virol. 71:(2):1997;1079-1088.
45. Price DL, Tanzi RE, Borchelt DR, Sisodia SS. Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet. 32:1998;461-493.
46. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med. 5:(1):1999;71-77.
47. Richardson WD, Westphal H. Requirement for either early region 1a or early region 1b adenovirus gene products in the helper effect for adeno-associated virus. J Virol. 51:(2):1984;404-410.
48. Ruitenberg MJ, Dijkhuizen PA, Hermens WTJMC, Blits B, Schoenmakers N, van Heerikhuize JJ, et al. Adeno-associated viral vector-mediated gene transfer of brain-derived neurotrophic factor reverses atrophy of lesioned rubrospinal neurons. Soc Neurosci Abstr. 25:1999;497.
49. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol. 63:(9):1989;3822-3828.
50. Sasahara M, Sato H, Iihara K, Wang J, Chue CH, Takayama S, et al. Expression of platelet-derived growth factor B-chain in the mature rat brain and pituitary gland. Brain Res Mol Brain Res. 32:(1):1995;63-74.
51. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci. 15:1995;6213-6221.
52. Senapathy P, Carter BJ. Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells. J Biol Chem. 259:(7):1984;4661-4666.
53. Snyder RO, Spratt SK, Lagarde C, Bohl D, Kaspar B, Sloan B, et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther. 8:(16):1997;1891-1900.
54. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 72:(2):1998;1438-1445.
55. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med. 5:(1):1999;78-82.
56. Szczypka MS, Mandel RJ, Donahue BA, Snyder RO, Leff SE, Palmiter RD. Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice. Neuron. 22:(1):1999;167-178.
57. Weitzman MD, Kyostio SR, Kotin RM, Owens RA. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA. 91:(13):1994;5808-5812.
58. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 215:1982;1237-1239.
59. Wu P, Phillips MI, Bui J, Terwilliger EF. Adeno-associated virus vector-mediated transgene integration into neurons and other non-dividing cell targets. J Virol. 72:(7):1998;5919-5926.
60. Xiao X, Xiao W, Li J, Samulski RJ. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol. 71:(2):1997a;941-948.
61. Xiao X, McCown TJ, Li J, Breese GR, Morrow AL, Samulski RJ. Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res. 756:(1-2):1997b;76-83.
62. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 72:(3):1998;2224-2232.
63. Yakinoglu AO, Heilbronn R, Burkle A, Schlehofer JR, zur Hausen H. DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. Cancer Res. 48:(11):1988;3123-3129.
64. Yakobson B, Koch T, Winocour E. Replication of adeno-associated virus in synchronized cells without the addition of a helper virus. J Virol. 61:(4):1987;972-981.
65. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. A 'humanized' green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol. 70:1996;4646-4654.
66. Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6:1999;973-985.